MiniMed Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MMED research report →
Range $16 – $30
Price Chart
About the company
MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. The company's diverse portfolio features essential tools like insulin pumps, continuous glucose monitoring (CGM) systems, infusion sets, specialized software platforms, and various supplementary accessories.
- CEO
- Que Thanh Dallara
- IPO
- 2026
- Employees
- 8,000
- HQ
- Northridge, CA, US
Get TickerSpark's AI analysis on MMED
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.50B
- P/E
- -13.39
- Fwd P/E
- 23.26
- PEG
- 0.13
- P/S
- 1.40
- P/B
- 1.24
- EV/EBITDA
- 25.78
- Div Yield
- 0.00%
- Gross Margin
- 53.85%
- Op Margin
- 0.53%
- Net Margin
- -10.21%
- ROE
- -9.11%
- ROIC
- 0.43%
Latest fiscal year · YoY change
- Revenue
- $3.10B+14.3%
- Gross Profit
- $1.68B+10.2%
- Op Income
- $49.00M
- Net Income
- $-331,000,000-32.4%
- EPS
- $-1.29-44.9%
- OCF Growth
- -240.7%
- FCF Growth
- -692.5%
- 52W High
- $24.43
- 52W Low
- $10.65
- 50D MA
- $19.03
- 200D MA
- $16.70
- Beta
- -3.71
- RSI (14)
- 37
- Avg Volume
- 8.48M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
MiniMed opened fiscal 2027 with faster-than-expected growth, early launch momentum for Flex and Go, and multiple pipeline milestones pulled in ahead of schedule.· September 1, 2026
- Q1 organic revenue grew 15.8% to $843 million, with U.S. up 13.1% and international up 16.9%.
- Management said growth benefited from an extra fiscal week, but even excluding it organic growth was in the low double digits versus 8.7% in Q4.
- Adjusted EBITDA was $83 million, with margin of 9.9%; excluding $8 million of pulled-forward investment and a $12 million FX remeasurement charge, margin would have been 12.2%.
- MiniMed raised full-year fiscal 2027 organic revenue growth guidance to about 10.5% from about 10%, while reaffirming adjusted EBITDA margin guidance of about 16%.
- Pipeline timing moved up again: Flex got CE Mark ahead of plan, Fit’s FDA filing was completed early, Vivera enrollment was completed ahead of schedule, and the next-gen sensor won IDE approval.
Q1 revenue was $843 million, up 15.8% organic year over year. U.S. organic revenue grew 13.1% and international grew 16.9%. Adjusted gross margin was 55.9%, adjusted EBITDA was $83 million, and adjusted EBITDA margin was 9.9%; excluding an $8 million pull-forward of investment and a $12 million FX remeasurement charge, margin would have been 12.2%. New pumps sold were 34,000, up 7.7%, and CGM attachment rate was 69%, up 500 basis points year over year. For the full year, management raised fiscal 2027 organic revenue growth guidance to approximately 10.5% from approximately 10% and reaffirmed adjusted EBITDA margin guidance of approximately 16%.
Que Dallara emphasized that MiniMed is executing its long-term strategy of building a full diabetes platform: smart pen, durable pump, patch pump, one algorithm, one app, one ecosystem. She highlighted strong early demand for Flex in the U.S., with new MiniMed prescribers up 24% and many new customers coming from MDI, and said international growth remains strong as the company expands sensor availability and launches new products. Her tone was confident and upbeat, repeatedly stressing that milestones are arriving earlier than planned and that the company is expanding its addressable market, especially in Type 2 diabetes and automated insulin delivery.
Chad Spooner focused on the financial quality of the quarter and the path to margin expansion. He said gross margin was 55.9%, ahead of expectations, and noted Simplera yields are trending better than expected, while adjusted SG&A was 36.1% of revenue and adjusted R&D was 13.6%. He broke out the quarter’s EBITDA headwinds as about $8 million of accelerated investment and a $12 million FX remeasurement charge, and said the company ended Q1 with about $207 million of cash, no debt, and an undrawn $500 million revolver. He also said separation and stand-up costs consumed $111 million of cash in the quarter, but excluding those items MiniMed generated $21 million of positive free cash flow.
Analysts pressed on whether Fit could still launch with 20,000 units of launch capacity if approval comes early, and management said it is running scenarios and planning additional capacity beyond that level. Questions also focused on whether Flex and other new products are causing patients and doctors to switch faster than expected; management said competitive conversions have doubled versus a year ago and that new pump starts are being driven by MDI patients, higher prescriber adoption, and new CGM-enabled workflows. Analysts asked about Type 2 attrition and international competition, and management said retention has improved across Type 1 and Type 2, they see no alarming attrition, and contested markets like France and the U.K. are still showing strong growth.
The call showed multiple sources of momentum at once: accelerated U.S. growth, double-digit international growth, and early traction from Flex, Go, and new sensor launches. Management sounded increasingly confident that the company’s broader ecosystem and upcoming products can expand share, improve retention, and push automated insulin delivery into a larger Type 2 population.
Some of Q1’s strength was helped by an extra week, so reported growth will normalize in Q2 and management acknowledged a likely waiting-mode effect ahead of new launches. Margin improvement still depends on better Simplera yields, reduced FX volatility, and second-half leverage, while the company is still absorbing separation-related cash outflows and has a number of regulatory and commercialization steps left before Fit, Vivera, and the next-gen sensor reach the market.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 9.6%
- Shares Outstanding
- 281.35M
- Float Shares
- 26.98M
of shares held by institutions
105 13F filers
Buy/sell ratio 8.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Massachusetts Financial Services Co | 9.42M | ▲ 1.08M |
| Price T Rowe Associates Inc | 4.00M | ▲ 3.98M |
| Frontier Capital Management Co LLC | 3.46M | ▲ 3.46M |
| Fmr LLC | 3.41M | ▲ 2.33M |
| Ubs Group AG | 2.74M | ▲ 2.32M |
| Blackrock, Inc. | 2.11M | ▲ 117.22K |
| Exoduspoint Capital Management, LP | 2.01M | ▲ 568.98K |
| Norges Bank | 1.96M | ▲ 1.96M |
| Healthcare Of Ontario Pension Plan Trust Fund | 1.72M | ▲ 1.34M |
| Ubs Am, A Distinct Business Unit Of Ubs Asset Management Americas LLC | 1.65M | ▲ 1.65M |
| Rock Springs Capital Management LP | 1.60M | ▲ 85.00K |
| Millennium Management LLC | 1.53M | ▼ 1.53M |
Held by 156 ETFs
Biggest fund positions in MMED by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 28, 26 | Dianaty Ali | other | 449 |
| Oct 15, 26 | Lofton Kevin E | other | 836 |
| Oct 15, 26 | Dianaty Ali | other | 11,108 |
| Oct 15, 26 | Chandrasena Gillian | other | 1,800 |
| Oct 15, 26 | Hopkins Robert (Bob) | other | 11,877 |
| Oct 15, 26 | Endicott David J. | other | 3,374 |
| Oct 15, 26 | Bricker Amy | other | 11,877 |
| Oct 15, 26 | Bricker Amy | other | 0 |
| Oct 15, 26 | Medtronic plc | other | 252,813,348 |
| Oct 9, 26 | Wicks Timothy A | other | 11,795 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MMED coverage
Recent articles, reports, and earnings notes.
No research on MMED yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MMED report →MiniMed Launches MiniMed Flex Pump in Europe to Expand Diabetes Care (Revised)
zacks.com · Nov 19
MiniMed Launches MiniMed Flex Pump in Europe to Expand Diabetes Care
zacks.com · Nov 18
MiniMed: The Split-Off Hangover Is Hiding A Full-Stack Product Cycle
seekingalpha.com · Nov 18
MiniMed Launches MiniMed Flex™, its Smallest and Most Discrete Insulin Pump, in Europe
prnewswire.com · Nov 17
FDA Clears MiniMed Fit Tubeless Insulin Pump with Seven-Day Wear
benzinga.com · Nov 16
FDA Clears MiniMed Fit™ -- World's First and Only Tubeless Insulin Pump with Up to Seven-Day Wear and Zero Interruptions
prnewswire.com · Nov 16
MiniMed to Participate in Upcoming Investor Conferences
prnewswire.com · Nov 5
MiniMed to Announce Its Fiscal Year 2027 Second Quarter Financial Results
prnewswire.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.